Table 3.

Associations between disease severity measures and lGF-1 levels and Ln adiponectin levels adjusted for age and sex.

Variable	Ln(adiponectin)		IGF-1
	β (95% CI)	p	β (95% CI)	p
DAS28-CRP, per 1 unit	−0.081 (−0.22–0.054)	0.2	−9.46 (−20.16–1.24)	0.08
Abnormal HAQ, > 0	−0.44 (−0.83 – −0.060)	0.02	−32.90 (−64.05 – −1.73)	0.04
CRP > 0.5 mg/dl	−0.18 (−0.52–0.15)	0.3	−28.39 (−54.44 – −2.34)	0.03
Ln(TNF-α)	0.029 (−0.047–0.10)	0.4	−7.82 (−13.36 – −2.28)	0.007
Ln(SJC)	0.074 (−0.15–0.30)	0.5	−18.55 (−35.59 – −1.50)	0.03
High SvdH, > 21	0.20 (−0.17–0.57)	0.3	−32.49 (−61.70 – −3.27)	0.03
Disease duration, per 1 yr	−0.0045 (−0.020–0.011)	0.6	−1.21 (−2.40 – −0.0094)	0.048
CCP-positive	0.093 (−0.29–0.48)	0.6	6.23 (−24.65–37.11)	0.7
Current prednisone	−0.30 (−0.62–0.017)	0.06	1.52 (−24.99–28.03)	0.9
Current anti-TNF	−0.073 (−0.40 – −0.25)	0.65	−30.2 (−54.6 – −5.7)	0.02
Current MTX	−0.018 (−0.35–0.31)	0.91	35.9 (11.5–60.3)	0.005

IGF-1: insulin-like growth factor 1; Ln: natural log-adjusted; DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; TNF-α: tumor necrosis factor-α; SJC: swollen joint count; SvdH: Sharp/van der Heijde method; CCP: cyclic citrullinated peptide antibody; MTX: methotrexate.